3Vote!
Business Wire (Free subscription) | 25/11/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) announced today that Charles Butler, the company’s vice president, investor relations and corporate communications, will present at Piper Jaffray’s 21st Annual Healthcare Conference at 1:30 p.m. EST / 10:30 a.m. PST on Tuesday December 1, 2009 in New York. Mr. Butler will discuss the company’s corporate strategy,...
3Vote!
Business Wire (Free subscription) | 24/11/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) announced today that it will hold its Fifth Annual R&D Day on Wednesday, December 2, 2009 from 10:00 a.m. EST / 7:00 a.m. PST to 2:00 p.m. EST / 11:00 a.m. PST in New York. Exelixis management will discuss the company’s development pipeline, corporate strategy and financial outlook. The event will be available via...
4Vote!
Medical News Today (Free subscription) | 20/11/2009
Exelixis, Inc. (Nasdaq:EXEL) reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors. XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation,...
3Vote!
Radon Mitigation Pittsburgh (Free subscription) | 19/11/2009
( EMAILWIRE.COM , November 19, 2009 ) Dallas, TX - Illumina, Inc. (NASDAQ:ILMN) plunged 6.65% to $29.18. The stock hit an intraday high and an intraday low of $31.19 and $28.14 respectively. In the last six months the stock went down over 20%. Illumina, Inc. is a developer, manufacturer and marketer of integrated systems for the large-scale analysis of genetic variation and biological function. The...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 18/11/2009
Exelixis (EXEL) was downgraded today by analysts at Merriman and the stock is now at $6.75, down $0.94 (-12.22%) on volume of 1,539,766 shares traded. The brokerage reduced the stock to Neutral from Buy. Over the last 52 weeks the stock has ranged from a low of $2.11 to a high of $8.00. Exelixis stock has been showing support around $7.24 and resistance...
3Vote!
Business Wire (Free subscription) | 18/11/2009
BOSTON--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors. XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors,...
3Vote!
Stock Market Analysis (Free subscription) | 18/11/2009
November 18, 2009 - Below is a list of the Top 15 biggest losing stocks today that have decent volume. These stocks are usually going down on bad news. I usually throw these on my watch list and monitor them for a bounce or a potential short trade. Biggest Stock Losers - 11/18/09 1. Oncolytics Biotech, Inc. (ONCY) - News 2. Tix Corporation (TIXC) - No News 3. United Online Inc. (UNTD) - News 4. Concur...
3Vote!
Business Wire (Free subscription) | 17/11/2009
BOSTON--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid tumors. XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors,...
3Vote!
Business Wire (Free subscription) | 13/11/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the company’s executive vice president and chief financial officer, will present at Lazard’s 6th Annual Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Wednesday, November 18, 2009 in New York. Mr. Karbe will discuss the company’s corporate strategy, financial outlook...
4Vote!
Jim Cramer's Mad Money (Free subscription) | 10/11/2009
Jim Cramer’s Mad Money Stock Picks for Friday November 6 2009. These are all of Jim Cramer’s stock picks that are a Buy! I bold my picks. Buy: Clean Energy Fuels (CLNE) Fuel Systems Solutions (FSYS) Applied Materials (AMAT) Macy’s (M) Urban Outfitters (URBN) Nordstrom (JWN) Targacept (TRGT) Intel (INTC) NVIDIA (NVDA) Family Dollar Stores (FDO) Caterpillar (CAT) Hain Celestial Group...
Explore : Apparel Stores,
Biotechnologies,
Computer industry,
Discount Stores,
Fairchild Semiconductor International,
Family Dollar Stores,
Integrated Circuits,
Nordstrom,
NVIDIA,
Retail,
Semi-Conductors,
Urban Outfitters,
Wal-Mart
3Vote!
Stock Market Analysis (Free subscription) | 09/11/2009
Below is a list of some of the largest stock gainers and losers so far in pre market for November 9, 2009. Check out my Hot Stocks to Watch page for the latest updates. Pre Market Stock Gainers - 11/9/09 East West Bancorp Inc. (EWBC) - 63 new banks reopened under EWBC ownership Compugen Ltd. (CGEN) - Compugen Announces Discovery of Genetic Biomarker for Predisposition to Type 2 Diabetes Ariad Pharmaceuticals...
Explore : Biotechnologies,
Channels,
Discovery,
Electronic Stores,
IT Services,
Markets,
Money,
RadioShack,
Retail,
Satyam Computer Services,
Stock markets,
Stocks
3Vote!
Business Wire (Free subscription) | 04/11/2009
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen abstracts related to the company’s development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. Interim data from ongoing phase 1 clinical trials of...
3Vote!
Business Wire (Free subscription) | 02/11/2009
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has amended its license agreement with Exelixis, Inc. (NASDAQ: EXEL) as a result of which Ligand is now entitled to receive royalties on net sales of future products from a mineralocorticoid receptor program and a one-time $75,000 payment for providing access to certain patent rights. Also, as a result of Ligand’s...
3Vote!
Rocky Mount Telegram - Business (Free subscription) | 30/10/2009
NEW YORK — Shares of biotechnology company Exelixis Inc. rose Friday after the company narrowe...
3Vote!
ABC News (Free subscription) | 30/10/2009
Exelixis' shares rise as revenue from new partnerships narrows 3rd-quarter loss
Videos